Kane Logo Cropped TransBG.png
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
31. Januar 2024 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™...
3239-KAN-Revyve_Box&Tube_LG-d2-FL
Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
02. November 2023 11:48 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today...
coactiv wound gel
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
25. Mai 2023 10:38 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its...